BioNTech (NASDAQ:BNTX) Now Covered by Analysts at Truist Financial

Equities researchers at Truist Financial started coverage on shares of BioNTech (NASDAQ:BNTX) in a research report issued on Friday, Marketbeat reports. The brokerage set a “buy” rating and a $172.00 price target on the stock. Truist Financial’s price objective would indicate a potential upside of 40.81% from the stock’s previous close.

A number of other research analysts also recently weighed in on the company. Jefferies Financial Group raised BioNTech from a “hold” rating to a “buy” rating and increased their target price for the company from $96.00 to $150.00 in a report on Tuesday, September 17th. Bank of America increased their price objective on shares of BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a research note on Monday, September 16th. HSBC boosted their target price on shares of BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a research report on Monday, October 7th. BMO Capital Markets reiterated an “outperform” rating on shares of BioNTech in a research report on Monday, December 2nd. Finally, UBS Group boosted their price objective on shares of BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research report on Wednesday, September 18th. Three research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $142.72.

BioNTech Stock Performance

Shares of BNTX stock opened at $122.15 on Friday. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average price of $114.07 and a 200-day moving average price of $103.06. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49. The firm has a market capitalization of $29.28 billion, a PE ratio of -58.17 and a beta of 0.18.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm’s revenue was up 38.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.73 EPS. As a group, equities research analysts expect that BioNTech will post -3.72 earnings per share for the current year.

Hedge Funds Weigh In On BioNTech

Hedge funds have recently made changes to their positions in the business. Planning Capital Management Corp raised its stake in BioNTech by 45,000.0% during the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after purchasing an additional 450 shares during the period. Blue Trust Inc. raised its position in shares of BioNTech by 491.1% during the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after buying an additional 388 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of BioNTech by 21.7% in the third quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock worth $74,000 after buying an additional 111 shares in the last quarter. Daiwa Securities Group Inc. boosted its position in shares of BioNTech by 430.3% during the second quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock worth $155,000 after acquiring an additional 1,562 shares during the last quarter. Finally, Caprock Group LLC purchased a new position in BioNTech during the second quarter valued at $206,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.